READOUT / 03 · CARDIAC CHANNEL
TB-500 Cardiac Research: Thymosin Beta-4, Heart Repair, and the Clinical Evidence
PINCH-ILK-Akt survival signaling, epicardial progenitors, cardiac-rupture prevention, and one completed human acute-MI trial — the heart literature, monitored as its own channel.
The survival signal: PINCH-ILK-Akt
TB-500 cardiac research traces back to one mechanistic result. In mice, thymosin beta-4 formed a functional complex with PINCH and integrin-linked kinase (ILK), activating the survival kinase Akt; it promoted cardiac and endothelial cell migration and, after coronary artery ligation, upregulated ILK and Akt, enhanced early myocyte survival and improved cardiac function [2]. That 2004 Nature paper is the spine of the cardiac story — it gave a molecular pathway for how the protein keeps heart cells alive after an ischemic insult.
This is a full-length thymosin beta-4 result. It is also the reason the heart became the most-studied organ for the protein, and the reason TB-500 cardiac research is searched at all. The consolidated cardiac review summarizes thymosin beta-4's role in protecting and regenerating heart tissue across these models [9].
Does TB-500 affect the heart?
In mice, thymosin beta-4 activated PINCH-ILK-Akt survival signaling and, after coronary ligation, improved early cardiomyocyte survival and cardiac function [2]. These effects are shown for full-length thymosin beta-4, not confirmed for the 7-mer in humans. The mechanism is the strongest part of the cardiac record; the human translation is the weakest.
Rebuilding the injured heart: progenitors, rupture, and engraftment
Beyond keeping cells alive, thymosin beta-4 was reported to rebuild. It induced adult epicardial progenitor mobilization and neovascularization of the ischemic myocardium, reactivating an embryonic developmental program in the adult heart [11]. Cardioprotection was observed with systemic dosing of the protein following ischemia in an animal model [8]. In mice after myocardial infarction, thymosin beta-4 prevented cardiac rupture and improved cardiac function [10].
More recently, in a porcine model of myocardial infarction, thymosin beta-4 increased cardiac cell proliferation and engraftment and improved repair when delivered with engineered mesenchymal stromal cells — a large-animal result published in 2021 [13]. Read together, these are a consistent regenerative signal for the full-length protein across mouse and pig models.
Is TB-500 cardioprotective after a heart attack?
Animal models report cardioprotection — systemic thymosin beta-4 after ischemia [8] and prevention of cardiac rupture post-MI in mice [10]. But the signal is not uniform: human data are limited to a completed acute-MI trial of thymosin beta-4 (NCT05984134), and the porcine work used engineered cell delivery rather than the peptide alone [13]. The 7-mer's cardiac effect in humans is not established.
Where the human cardiac evidence actually stands
The human cardiac record is one line, and it must be read carefully. A human acute-myocardial-infarction trial of thymosin beta-4 (NCT05984134) is recorded as completed [12]. That is the registry status. Published peer-reviewed efficacy outcomes for the TB-500 fragment in humans are not established, and the trial studied the protein, not the 7-mer [12]. An earlier injectable thymosin beta-4 trial was withdrawn, so the presumed clinical pipeline overstates the current evidence if read as momentum [12].
So the cardiac channel ends where the data end. The mechanism is strong and reproducible in animals — PINCH-ILK-Akt survival signaling [2], progenitor mobilization [11], rupture prevention [10], large-animal engraftment [13]. The human translation is a single completed trial with no published efficacy readout for the fragment [12].
Did thymosin beta-4 improve outcomes in cardiac clinical trials?
A human acute-myocardial-infarction trial of thymosin beta-4 (NCT05984134) is recorded as completed [12]. Published peer-reviewed efficacy outcomes for the TB-500 fragment in humans are not established [12]. A registry completion is a milestone, not a result — no efficacy conclusion should be drawn from it.